Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimal Balance Alfapump® System Feasibility Study (OPTIMALBALANCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03032211
Recruitment Status : Withdrawn (Change in company strategy)
First Posted : January 26, 2017
Last Update Posted : January 26, 2017
Sponsor:
Information provided by (Responsible Party):
Sequana Medical N.V.

Brief Summary:

1. Summary of Clinical Investigation

A summary of the clinical investigation is provided below and includes the primary objective of the study, the safety and feasibility endpoints, the number of subjects to be enrolled, the study duration, the subject follow-up and the inclusion/exclusion criteria.

  1. Primary Objective

    The primary objective of the study is to evaluate the safety and feasibility of the alfapump® System indication for use in the management of fluid in NYHA Class III and ambulatory NYHA Class IV heart failure patients who have an eGFR of > 15 to < 60 mL/min/1.73m2.

  2. Study Endpoints

    1. Primary Safety Endpoint

      The primary safety endpoint will be an assessment of the occurrence of adverse events (AEs) and serious adverse events (SAEs) related to:

      1. Surgical implant of the alfapump®
      2. Device malfunctions
      3. Dialysate infusion
    2. Secondary Safety Endpoints

      The secondary endpoint will be an assessment of:

      1. Time to first hospitalization related to fluid management after the activation of the alfapump® System and initiation of dialysate infusion has occurred
      2. Rate of occurrence of re-hospitalizations related to fluid management
      3. All-cause mortality
    3. Assessment of Feasibility for Fluid Management in Heart Failure Indication The feasibility of the alfapump® System for management of fluid in NYHA Class III and ambulatory NYHA Class IV heart failure patients with renal dysfunction will be assessed by the net fluid balance as measured by the ability of the alfapump® System to move more fluid to the bladder than dialysate instilled.

Condition or disease Intervention/treatment Phase
Heart Failure Device: Alfapump Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Feasibility Clinical Study of Osmotic Pump Treatment in Fluid Management to Achieve Optimal Fluid Balance in NYHA Class III and Ambulatory NYHA Class IV Heart Failure Patients Who Have an Estimated Glomerular Filtration Rate of > 15 to < 60 mL/Min/1.73m2
Estimated Study Start Date : December 31, 2017
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: Treatment
Alfapump
Device: Alfapump
Implant Alfapump® System




Primary Outcome Measures :
  1. Occurrence of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: Q1 2017 and Q3 2017 ]
    4 weeks after the third patient implanted an initial safety review will be done and after the last patient completed 3 months of dialysate administration.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Males or females ≥ 18 years and < 80 years of age
  • Patients exhibiting physical signs of excessive fluid retention (i.e. elevated JVD, peripheral edema, ascites, pulmonary edema, weight gain etc.)
  • Patients with an eGFR by the Modification of Diet in Renal Disease (MDRD) of > 15 to < 60 mL/min/1.73m2
  • Patients with a brain natriuretic peptide (BNP) ≥ 150 pg/mL and/or N-terminal prohormone of brain natriuretic peptide (NT-proBNP) ≥ 600 pg/mL at time of screening or BNP ≥ 100 pg/mL and/or NTproBNP ≥ 400 pg/mL
  • Patients who have a Six Minute Walk Test (SMWT) exercise capacity between 100 and 400 meters
  • Patients presenting with NYHA Class III or ambulatory NYHA Class IV heart failure who have been on optimal medical management (OMM) based on current heart failure practice guidelines and who are failing to respond to or cannot tolerate one or more of the following interventions:

    1. Treatment with diuretic therapy
    2. Treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for at least 30 days
    3. Treatment with nitrates and/or vasodilators at the investigator's discretion
    4. Treatment with beta-blockers for at least 90 days
    5. Treatment with cardiac resynchronization therapy (CRT)
    6. Treatment with an automatic implantable cardioverter defibrillator (AICD)
  • Patients who demonstrate compliance with the current medical regimen as reported by the treating physician

Enrollment Exclusion Criteria

  • Patients presenting with acute decompensated heart failure requiring hospitalization for management of their symptoms (i.e. hospitalization for exacerbation of chronic heart failure manifested by signs and symptoms requiring intravenous and/or more aggressive therapy)
  • Patients with ascites on physical examination resulting predominantly from right heart failure
  • Patients who have an indication for and are candidates for CRT but who have not been treated with CRT
  • Patients who have an indication for and are candidates for an AICD but who have not been implanted with an AICD
  • Patients with reversible causes of heart failure which may be remedied by conventional surgery or other interventions
  • Patients with an eGFR by MDRD < 15 or > 60 ml/min/1.73m2
  • Patients with a body mass index (BMI) < 18 kg/m2or > 35 kg/m2
  • Patients with severe pulmonary disease by history (i.e. severe chronic obstructive pulmonary disease, severe hypoxia or a pulmonary artery mean pressure >40 mm Hg)
  • Patients who have experienced a myocardial infarction (MI) within the past 90 days
  • Patients who have experienced a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 90 days
  • Patients who have undergone cardiac surgery or other major surgery within the past 90 days
  • Patients who are candidates for and require a concomitant surgical procedure [i.e. coronary artery bypass graft (CABG), valvular surgery, etc.
  • Patients who are candidates for and require temporary or durable mechanical circulatory support [i.e. intra-aortic balloon pump (IABP), ventricular assist device (VAD), extracorporeal membrane oxygenation (ECMO)]
  • Patients with confirmed untreated abdominal aortic aneurysm (AAA) > 5 cm in diameter diagnosed within the past six months
  • Patients with active systemic or uncontrolled infections
  • Patients who are pregnant (Note: Negative pregnancy test will be required in all women - Patients with known alcohol or illicit drug abuse or dependence within the previous three months
  • Patients who are currently enrolled or who have participated in the past 30 days in another therapeutic and/or interventional clinical study
  • Patients with technical obstacles that pose an inordinately high surgical risk in the judgment of the Investigator
  • Patients who have any underlying condition that, in the opinion of the Investigator, would disqualify the patient for inclusion in the study, limit survival to less than one year, or not permit valid consideration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03032211


Locations
Layout table for location information
Hungary
Military Hospital - State Health Centre
Budapest, Hungary, 1134
Sponsors and Collaborators
Sequana Medical N.V.
Layout table for additonal information
Responsible Party: Sequana Medical N.V.
ClinicalTrials.gov Identifier: NCT03032211    
Other Study ID Numbers: 2016-CHF-003
First Posted: January 26, 2017    Key Record Dates
Last Update Posted: January 26, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Study cancelled, therefore not applicable at time of answering this remark.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases